Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 29, 2024British Journal of HaematologyOpen Access

Impact of elranatamab on quality of life: Patient‐reported outcomes from MagnetisMM‐3

View Full Paper
Ask AI
Bookmark
Share

Authors

MMMohamad MohtyNBNizar J. BahlisANAjay K. Nooka

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Mohty et al. (2024) studied this question.

synapsesocial.com/papers/68e76d08b6db6435876e2e3fhttps://doi.org/10.1111/bjh.19346
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium2026 · 6 citations
  2. 2Efficacy and safety of elranatamab in patients with relapsed or refractory multiple myeloma: A US subgroup analysis from MagnetisMM‐32026
  3. 3Elranatamab: Mechanism of Action, Clinical, and Translational Science.2026
  4. 4Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma2024 · 17 citations
  5. 5Real-world effectiveness and safety of elranatamab in patients with relapsed/refractory multiple myeloma: Preliminary results from the prospective, non-interventional MagnetisMM-16 study.2026